Sigyn Therapeutics: Pioneering the Future of Disease Treatment with Breakthrough Blood Purification Technology

​

• Game-changing blood purification technology designed to target a broad range of viral, bacterial, and inflammatory agents offers a versatile solution for emerging global health threats.

​

• Potential to treat serious conditions like sepsis, emerging viral infections, and inflammatory disorders that shorten the lives of those with end-stage renal disease (ESRD). Thus, positioning Sigyn as a key player in both infectious disease and chronic illness treatments

​

• Significant advantages in terms of efficiency and scalability, as it works seamlessly with existing dialysis and CRRT machines, making it a potential cost-effective option for hospitals worldwide.

​

• With its promising technology, growing market need for blood purification, and dialysis industry relationships, Sigyn Therapeutics represents a compelling investment opportunity in the healthcare sector.​

 

Sigyn Therapeutics, Inc. (OTCQB: SIGY), a pioneering company in the field of blood purification therapies, presents a significant investment opportunity for those seeking exposure to the rapidly evolving healthcare market. With its innovative Sigyn Therapy™, Sigyn is positioning itself as a potential game-changer in addressing both emerging pandemic threats and prevalent conditions like sepsis and inflammatory disorders that shorten the lives to those with end-stage renal disease (ESRD). This report outlines why Sigyn Therapeutics is a compelling buy for investors, based on recent developments, the strategic market potential, and the company's strong technological foundation.

​

Sigyn Therapy: A Breakthrough Technology

Sigyn Therapeutics has developed Sigyn Therapy™, a blood purification technology with the unique ability to remove viral pathogens, bacterial toxins, inflammatory cytokines, and other harmful agents from the bloodstream. This innovative approach targets a broad range of conditions, from life-threatening infections like COVID-19 and Ebola to the more prevalent and deadly problem of sepsis.

The versatility of Sigyn Therapy™ is one of its major strengths. Unlike traditional antiviral treatments, which often target specific viral strains, Sigyn Therapy™ works across a wide range of viruses, offering a broad-spectrum solution to emerging and ongoing global health crises. This capability is critical, especially as new viral threats, such as virulent strains of influenza, bird-flu virus and Mpox, continue to emerge and spread across the globe.

​

Market Context: The Growing Need for Blood Purification Therapies

The need for advanced blood purification technologies has never been more urgent. As evidenced by the ongoing global pandemic and the continued emergence of novel viruses, there is a clear demand for effective, rapid-response treatments that can address viral outbreaks. Sigyn Therapy™ meets this need head-on by offering a mechanism to purify the blood of pathogens, toxins, and inflammatory agents, thus reducing viral replication and inflammation as a means to improve patient outcomes.

​

In addition to infectious diseases, Sigyn Therapy™ has significant applications in treating endotoxemia and sepsis—conditions that are major causes of death in hospitals worldwide. Sepsis, caused by bacterial infections, leads to organ failure and is the number one cause of death in U.S. hospitals. Sigyn Therapy™ has been shown to reduce the circulating presence of both endotoxin and inflammatory cytokines from human blood plasma to offer a potential life-saving treatment for sepsis patients.

​

The U.S. government has recognized the importance of blood purification therapies, with agencies such as DARPA (Defense Advanced Research Projects Agency) supporting the development of breakthrough technologies in this field. In fact, the first four therapies approved to treat COVID-19 under FDA emergency-use authorization were blood purification technologies.  Sigyn's technology has been designed to be more efficient, scalable, and cost-effective than its predecessors, giving it a competitive edge in both the pandemic and hospital treatment markets.

​

The Sigyn Therapy™ Advantage

What sets Sigyn Therapy™ apart from other treatments is its broad-spectrum mechanism of action. While traditional antiviral drugs are typically designed to target specific viruses, Sigyn Therapy™ has the capacity to target a wide range of viral strains, bacterial toxins, and inflammatory cytokines. This makes it an ideal solution for combating emerging and unknown viruses that often evade current treatments.

Sigyn Therapy™ also offers significant advantages over existing therapies in terms of efficiency. The device processes the bloodstream of an average individual about 15 times during a four-hour treatment, enabling rapid and thorough purification. Moreover, it is designed to work with existing dialysis and CRRT machines, making it easier to implement in hospitals worldwide without requiring costly new infrastructure.

​

Addressing the ESRD Market

Sigyn Therapeutics' potential is not limited to infectious disease. The company is also focused on improving the lives of the 550,000 patients in the United States suffering from ESRD, who rely on dialysis for survival. These patients often experience inflammation and endotoxemia, which significantly shorten their lives and reduce the effectiveness of their dialysis treatments. By incorporating Sigyn Therapy™ into regular dialysis treatments, the company could improve patient outcomes and extend life expectancy, offering a profound benefit to the dialysis industry.

​

This dual-use capability of Sigyn Therapy™—both for acute viral infections and chronic conditions like ESRD—gives the company a unique competitive position in the healthcare market. If successful, this could substantially increase revenues of dialysis companies such as Fresenius Medical Care and DaVita Inc.,who dominate the dialysis industry in North America.

​

Strong Clinical Foundation and Future Growth Potential

Sigyn's clinical strategy is robust, with the company planning to conduct a feasibility study in ESRD patients with endotoxemia and concurrent inflammation. The completion of this study will lay the groundwork for pivotal clinical trials and, ultimately, potential regulatory clearance for treat emerging viral pathogens, sepsis and endotoxemia and concurrent inflammation that are prevalent in ESRD patients. With successful clinical trials, Sigyn Therapy™ could become a critical component in the treatment of life-threatening conditions that are not addressed with drug therapies. Thus, establishing the company as a leader in the emerging blood purification industry.

​

Moreover, Sigyn TherapyTM has a mechanism of action that may enhance the benefit of antiviral drugs.  This could be a key advantage in the global race to advance post-exposure strategies to treat emerging viruses that could fuel the next pandemic. 

​

Oncology Pipeline and Broader Applications

In addition to its focus on blood purification and infectious diseases, Sigyn Therapeutics also has an oncology pipeline featuring promising therapies like ImmunePrep™, ChemoPrep™, and ChemoPure™. These treatments aim to enhance the delivery of immunotherapies and chemotherapies while reducing toxicity, potentially opening up additional revenue streams for the company. With a diversified portfolio, Sigyn is well-positioned to become a key player in both infectious disease and oncology treatment sectors.

​

Conclusion

Sigyn Therapeutics represents a compelling investment opportunity for those looking to invest in a company at the intersection of healthcare innovation, infectious disease, and chronic illness treatment. With the growing prevalence of viral outbreaks and the increasing demand for advanced blood purification therapies, Sigyn's broad-spectrum approach to blood purification positions it as a leader in the space.

The company's ability to treat a wide range of conditions, provides significant market potential and avenues for growth. As the global healthcare landscape continues to evolve, Sigyn's unique technology and clinical strategy make it a strong contender for future success.

Sigyn Therapeutics offers a rare combination of technological innovation, market opportunity, and strategic vision. For investors seeking exposure to a high-growth healthcare company with the potential to make a global impact, Sigyn represents a compelling opportunity to buy and hold for the future.

​

Legal Disclosures and Disclaimers

Green Planet Microcaps is not a registered investment adviser. The information that we provide from our website or newsletters is not, and should not be construed in any manner, to be investment advice. All opinions and information provided on this site are for educational and research purposes. Green Planet Microcaps encourages all readers to do their own due diligence and research when determining which investment strategies are best suited for them or to seek the advice of an investment professional.

​

Any information provided by Green Planet Microcaps should not be construed by any subscriber or prospective subscriber as a solicitation by Green Planet Microcaps to effect, or attempt to effect, any transaction in any security. Investments in the securities markets, and especially in private securities of small start-up companies, are incredibly and highly speculative and involve substantial risk that your entire investment could be lost. The information that we provide or that is derived from our website and/or newsletters should not be a substitute for advice from an investment professional. We encourage you to obtain personal advice from your professional investment advisor and to make independent investigations before acting on the information that you obtain from Green Planet Microcaps or derive from our website and/or newsletters. Only you can determine what level of risk is appropriate for you.

​

Specifically, we advise all readers and subscribers to seek advice from a registered professional securities representative before deciding to purchase or trade in stocks or any securities presented on this website and/or in a particular newsletter. All information provided regarding the companies featured comes from the companies themselves, SEC filings, news releases, private placement memoranda, company websites as well as other sources of publicly available information. The profiles of these highlighted public and private companies are not in any way a solicitation or recommendation to buy, sell, or hold these or any other securities.

​

Most of the information on our website and/or newsletters or that we otherwise provide is derived directly from information published by the companies on which we report and/or from other sources we believe are reliable, without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. The information may contain discussions of, or provide access to, certain positions and recommendations as of a specific date. Due to various factors, including, but not limited to, changing market conditions, such discussions and positions/recommendations may no longer be reflective of current discussions and positions/recommendations. We do not in any way warrant or guarantee the success of nor endorse any action which you take in reliance on the information that we provide or that is derived from our website.

​

Investors should not rely solely on the information contained on this website or in any specific newsletter. Rather, investors should use the information contained on this Website and/or in newsletters as a starting point for doing additional independent research on the featured private and public companies. The advertisements within this newsletter are not to be construed as offers to purchase securities in the companies which may be the subject of such advertisements pursuant to federal or state law or the laws of any foreign jurisdiction.

Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects’”, “will,” “anticipates,” “estimates,” “believes,” “understands” or that by statements indicating certain actions “may,” “could,” or “might” occur. There is no guarantee past performance will be indicative of future results. The accuracy or completeness of the information in this newsletter is only as reliable as the sources they were obtained from.​

 

Green Planet Microcaps was not compensated for this article and will not be liable for any consequential, incidental, punitive, special, exemplary or indirect damages resulting directly or indirectly from the use of or reliance upon any material provided by Green Planet Microcaps or derived from Green Planet Microcap’s website and/or newsletters. Green Planet Microcaps shall not be responsible or liable for any loss or damages related to, either directly or indirectly, (1) any decline in market value or loss of any investment; (2) a subscriber’s inability to use or any delay in accessing Green Planet Microcaps website or any other source of material provided by Green Planet Microcaps including newsletters; (3) any absence of material on Green Planet Microcaps; (4) Green Planet Microcaps failure to deliver or delay in delivering any material or (5) any kind of error in transmission of material. Green Planet Microcaps and each subscriber acknowledge that, without limitation, the above-enumerated conditions cannot be the probable result of any breach of any agreement between Green Planet Microcaps and the subscriber.

​

Green Planet Microcaps is not affiliated with any brokerage firm and does not endorse or recommend any specific brokerage firm. Green Planet Microcaps is not and will not be responsible for any trades made by a broker on the subscriber’s behalf under any circumstances.